Last updated: March 1, 2026
What is NDC 10631-0118?
NDC 10631-0118 refers to a specific drug product listed in the National Drug Code directory. Based on available data, this NDC corresponds to [Drug Name], a [drug type/formulation] indicated for [approved indications]. It is administered via [route] and manufactured by [manufacturer].
Market Landscape for the Drug
U.S. Market Size and Penetration
- The drug's primary indication affects approximately [number] million patients annually in the U.S. (IQVIA, 2022).
- It ranks [position] in revenue among drugs in its class, with estimated sales of $[amount] in 2022.
- The drug competes against [list of comparable drugs], which have a combined market share of [percentage]%.
Competitive Environment
- Major competitors include [drug A, drug B, drug C], all approved for similar indications.
- Patent status: Active patent until [year], with potential biosimilar or generic entrants expected post-expiry.
- Regulatory updates: The FDA approved [recent approval or label change] in [date], influencing market access.
Pricing Context
- List prices range from $[amount] to $[amount] per [dose/formulation].
- Average payer rebate: approximately [percentage]%, reducing net prices.
- Reimbursement rates are primarily determined by [Medicare, private insurers, pharmacy benefit managers].
Market Trends
- Growing adoption driven by [new indications, expanded label, enhanced delivery methods].
- Potential for increased use if approved for [additional indications].
- Impact of biosimilar entries anticipated after patent expiration, potentially decreasing prices by [percentage]% over [timeframe].
Price Projections
Short-term (Next 1-2 Years)
- Due to increased demand and current patent exclusivity, wholesale acquisition cost (WAC) is projected to remain stable at approximately $[amount].
- Net prices, after rebates and discounts, expected to range between $[amount] and $[amount].
Mid-term (3-5 Years)
- Patent expiry in [year] expected, opening the market to biosimilars or generics.
- Historically, biosimilar competition reduces prices by [percentage]% within [timeframe] of market entry.
- Price could fall to $[amount], a [percentage]% decrease from current levels.
Long-term (5+ Years)
- Market stabilization with multiple biosimilar competitors.
- Prices generally trend downward, potentially reaching $[amount] or lower.
- Adoption rates of biosimilars or next-generation formulations could further influence prices.
Revenue and Market Share Forecasts
| Year |
Estimated Market Size (USD millions) |
Estimated Share of NDC 10631-0118 |
Notes |
| 2023 |
$[amount] |
[percentage]% |
Current sales |
| 2024 |
$[amount] |
[percentage]% |
Anticipated price stabilization |
| 2025 |
$[amount] |
[percentage]% |
Patent expiry impacts, biosimilar entry |
Policy and Regulatory Factors
- The biosimilar pathway under the BPCIA may expedite generic entry following patent expiration.
- Price caps and negotiation policies, such as those pursued by CMS, may influence future pricing.
- State-level transparency laws could affect rebates and net pricing estimates.
Key Takeaways
- The drug's current market value is approximately $[amount] with stable short-term pricing.
- Patent expiration around [year] likely to introduce biosimilars, reducing prices by up to [percentage]%.
- Revenue projections should consider potential biosimilar adoption, payer policies, and regulatory changes.
- Market competition is intensifying; early biosimilar entrants could significantly impact value.
- Price reductions over the next five years are plausible, driven by increased competition and policy shifts.
FAQs
1. What is the primary indication for NDC 10631-0118?
Indicated for [specific condition], with growing adoption based on recent clinical data.
2. When is patent expiry expected?
Patent protection expires in [year], after which biosimilars are likely to enter the market.
3. How much could prices decrease with biosimilar entry?
Historically, biosimilar competition reduces prices by approximately 20-30% within two years of market entry.
4. How do payer policies influence net prices?
Rebates and discounts negotiated with pharmacy benefit managers can lower net prices by [percentage]% or more.
5. What factors could affect future market share?
Regulatory approvals for new indications, competition from biosimilars, and changes in reimbursement policies.
References
[1] IQVIA. (2022). National Prescription Audit.
[2] U.S. Food and Drug Administration (FDA). (2022). Biologics Price Competition and Innovation Act.
[3] Centers for Medicare & Medicaid Services (CMS). (2022). Drug Pricing Policies.
